- Home
- ALZN vs IDAI Comparison
ALZN vs IDAI Comparison
Compare ALZN & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- IDAI
- Stock Information
- Founded
- ALZN 2016
- IDAI 2016
- Country
- ALZN United States
- IDAI United States
- Employees
- ALZN N/A
- IDAI N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- IDAI Computer Software: Prepackaged Software
- Sector
- ALZN Health Care
- IDAI Technology
- Exchange
- ALZN Nasdaq
- IDAI Nasdaq
- Market Cap
- ALZN 7.5M
- IDAI 7.7M
- IPO Year
- ALZN 2021
- IDAI N/A
- Fundamental
- Price
- ALZN $2.32
- IDAI $2.98
- Analyst Decision
- ALZN Strong Buy
- IDAI
- Analyst Count
- ALZN 1
- IDAI 0
- Target Price
- ALZN $45.00
- IDAI N/A
- AVG Volume (30 Days)
- ALZN 71.9K
- IDAI 23.5K
- Earning Date
- ALZN 09-10-2025
- IDAI 08-14-2025
- Dividend Yield
- ALZN N/A
- IDAI N/A
- EPS Growth
- ALZN N/A
- IDAI N/A
- EPS
- ALZN N/A
- IDAI N/A
- Revenue
- ALZN N/A
- IDAI $3,366,415.00
- Revenue This Year
- ALZN N/A
- IDAI $25.13
- Revenue Next Year
- ALZN N/A
- IDAI $48.09
- P/E Ratio
- ALZN N/A
- IDAI N/A
- Revenue Growth
- ALZN N/A
- IDAI N/A
- 52 Week Low
- ALZN $2.06
- IDAI $1.43
- 52 Week High
- ALZN $22.23
- IDAI $18.75
- Technical
- Relative Strength Index (RSI)
- ALZN 40.27
- IDAI 54.65
- Support Level
- ALZN $2.34
- IDAI $2.71
- Resistance Level
- ALZN $2.53
- IDAI $3.08
- Average True Range (ATR)
- ALZN 0.13
- IDAI 0.17
- MACD
- ALZN 0.02
- IDAI 0.01
- Stochastic Oscillator
- ALZN 29.03
- IDAI 73.96
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.